AUS
NZ
UK
CA
USA
IND
Highlights
- PTX-100 receives fast-track status from FDA
- Promising early results in treating T-cell lymphoma
- Phase 2 trials underway across multiple regions
Prescient Therapeutics (ASX:PTX) has achieved a key regulatory milestone, with its lead drug candidate PTX-100 receiving fast-track designation from the US Food and Drug Administration (FDA). This designation is a major step forward in advancing PTX-100 as a potential treatment for adults with relapsed or refractory mycosis fungoides, the most common subtype of cutaneous T-cell lymphoma (CTCL).
The FDA’s fast-track program is designed to speed up the development and review of treatments targeting serious conditions with limited existing options. For Prescient Therapeutics, this designation signals strong support for PTX-100’s therapeutic potential and opens up a more streamlined regulatory path.
PTX-100, a targeted cancer therapy, has already shown encouraging results in earlier clinical trials. A completed Phase 1b study enrolled 19 patients with various forms of T-cell lymphoma, demonstrating an overall response rate of 42% among those evaluated. Notably, six out of seven patients with CTCL experienced clinical benefits, with some maintaining progression-free survival (PFS) for over 10 months. This outcome compares favorably to the typical PFS of approximately 3.1 months for current standard treatments such as vorinostat.
With this regulatory green light, Prescient is moving forward with its clinical development strategy. The company recently launched its Phase 2a trial in Melbourne at the Epworth Freemasons hematology unit. This open-label study will assess two dosage levels of PTX-100 in around 40 patients with relapsed or refractory CTCL. Professor Miles Prince, a global authority in CTCL treatment, will lead the trial as principal investigator. Additional Phase 2a studies are planned across the US, Australia, and Europe.
According to the company, the fast-track designation will facilitate ongoing discussions with the FDA regarding trial design, endpoints, and broader regulatory considerations. These efforts are intended to support PTX-100’s progress toward a registration-enabling trial and ultimately commercial availability.
One patient from the original Phase 1b study continues to receive PTX-100 under Australia’s compassionate access scheme, having achieved a complete response. This ongoing case highlights the potential long-term benefits of the therapy and strengthens its profile as a viable option for patients with few alternatives.
Prescient Therapeutics (PTX) appears well-positioned to make a significant impact in the CTCL treatment landscape as PTX-100 moves through its next stages of clinical development.
